153 results
6-K
EX-99.1
BLU
Bellus Health Inc
2 Jun 23
Notice of Annual and Special Meeting of Shareholders
4:25pm
and Benefits – The board shall review and approve, as appropriate:
the overall structure of the Company’s total compensation strategy, including
6-K
EX-99.2
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
patent term extensions for our intellectual property;
our business strategy; and
our development and partnership plans and objectives.
The preceding … enrichment strategy;
continuing feedback and discussions with the FDA and other regulatory authorities regarding the design of the CALM Phase 3 program
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
, acceptability to regulatory agencies and impact of its enrichment strategy, continuing feedback and discussions with the FDA and other regulatory authorities
6-K
EX-99.2
BLU
Bellus Health Inc
27 Apr 23
Material Change Report
6:04am
such expense. Parent, after prior consultation with the Company, shall have the principal responsibility for devising and implementing the strategy
6-K
EX-99.1
BLU
Bellus Health Inc
5 Apr 23
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating
7:01am
results include but are not limited to: the intended benefits, acceptability to regulatory agencies and impact of its enrichment strategy, continuing
6-K
EX-99.2
cg70g
30 Mar 23
Notice of Annual and Special Meeting of Shareholders
11:22am
6-K
EX-99.1
jxgik36b 6x
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.2
85t6en2glrvybxnl 6o
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
33nsy
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
jw4fa
14 Nov 22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
4:03pm
6-K
EX-99.1
jx5n8qokw
10 Nov 22
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
4:01pm
6-K
EX-99.1
hnf75rpcowjn1 4vt0r
11 Oct 22
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
7:00am
6-K
EX-99.1
55pfgmh9
16 Sep 22
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022
4:40pm
6-K
EX-99.1
ohwwo2p
6 Sep 22
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
7:00am
F-10
ius8rlvbqlp255aew7d
26 Aug 22
Registration of securities (Canada)
4:48pm
6-K
EX-99.1
vi1u xxtpbuw41ate6
22 Aug 22
Bellus Health Inc. 6-K
7:01am
6-K
EX-99.2
13sr6jnudc7fi
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.1
1ly6 erjirlr
10 Aug 22
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
4:31pm
SUPPL
fyl71f wl
15 Jul 22
Supplemental materials (foreign)
7:01am
SUPPL
yz0db73i uz85nibc
13 Jul 22
Supplemental materials (foreign)
5:01pm